The Anti-Interleukin-1 in Diabetes Action trial (AIDA)

The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes.

Sites Include:

• Aalborg Hospital (Aalborg, Denmark)
• Aarhus University Hospital (Aarhus, Denmark)
• Bispebjerg University Hospital (Copenhagen, Denmark)
• German Diabetes Centre (Dusseldorf, Germany)
• Hospital Arnau de Vilanova (Lleida, Spain)
• Hospital Universitario Insular de Gran Canaria (Las Palmas de GC, Spain)
• Hospital de Cruces (Barakaldo, Spain)
• Hospital Santa Creu i Sant Pau (Barcelona, Spain)
• Hvidovre University Hospital (Hvidovre, Denmark)
• Köge Hospital (Köge, Denmark)
• Leiden University Medical Center (Leiden, Netherlands)
• Malmö University Hospital (Malmö, Sweden)
• Medical University of Bialystok (Bialystok, Poland)
• Munich University of Technology (Munich, Germany)
• Nordsjællands Hospital Hilleröd (Hilleröd, Denmark)
• Semmelweis Medical School (Budapest, Hungary)
• Steno Diabetes Center (Gentofte, Denmark)
• Ulm University (Ulm/Donau, Germany)
• University Campus Bio-Medico (Rome, Italy)
• University Children's Hospital (Ljubljana, Slovenia)
• University Hospital Zürich (Zürich, Switzerland)
• University Hospital Frankfurt am Main (Frankfurt, Germany)
• Vilnius University Hospital (Vilnius, Lithuania)

Click here for AIDA Study website

JDRF: 7-2005-1154